Latest by Sony Salzman
Although several HCV drugs can cure almost all infections regardless of viral genotype, picking the right drug will depend on each patient's medical history, level of liver damage, and coinfections.
But given cost concerns, advocates question whether the benefits are enough to warrant dumping F/TDF as the go-to PrEP option.
Experts Flummoxed By Conflicting New Data on STIs, HIV, and Long-Term Contraception in Sub-Saharan Africa
ECHO trial results and follow-up studies find unexpectedly low rates of some STIs among users of certain long-term hormonal contraceptives. They also find high HIV rates (unrelated to the contraceptives) that suggest considerable value for PrEP integration.
World Health Organization Updates Guidance on Dolutegravir After Reassuring Data Regarding Safety in Early Pregnancy
New study results leave many experts feeling they went too far in their concerns over birth defect risks associated with the drug.
Will potential study participants choose a vaccine trial over getting access to PrEP?
Six thousand HIV researchers and experts are expected to make their way to Mexico City for the 10th International AIDS Society Conference on HIV Science, which will feature more than 1,000 abstracts highlighting the latest findings in HIV treatment, prevention, and public health policy.
"The biggest barrier to care for transgender people is a lack of knowledgeable providers," said lead author Joshua D. Safer, M.D., with Mount Sinai Medical System.
Could home-based self-swabs and mobile technology be helpful tools in the future of HIV prevention?
No meaningful difference was found in either injectable or implant birth control when compared to an IUD.
Starting July 1, some HIV meds that are widely used will be excluded from their list.